Drug treatments for attention-deficit hyperactivity disorder in young people

Advances in Psychiatric Treatment

Volumn 15, Issue 3, 2009, Pages 162-171

  Bates, Gordon ^a  

^a London Huntercombe Manor Hospital   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATOMOXETINE; CARBOXYLESTERASE; CLONIDINE; METHYLPHENIDATE; MODAFINIL; PLACEBO; PSYCHOSTIMULANT AGENT;

ANOREXIA; APPETITE; ARTICLE; ATTENTION DEFICIT DISORDER; BODY HEIGHT; BODY WEIGHT; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMORBIDITY; DEPRESSION; DISEASE ASSOCIATION; DISEASE EXACERBATION; DOSE CALCULATION; DRUG ABUSE; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG RELEASE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPILEPSY; FAMILY HISTORY; GASTROINTESTINAL IRRITATION; GENETIC POLYMORPHISM; GROWTH RETARDATION; HEART ARRHYTHMIA; HUMAN; HYPERTENSION; INSOMNIA; LIVER DYSFUNCTION; PSYCHOPHARMACOLOGY; PSYCHOPHARMACOTHERAPY; REBOUND HYPERTENSION; SEDATION; SIDE EFFECT; STEVENS JOHNSON SYNDROME; SUDDEN DEATH; SUICIDAL IDEATION; TIC; WEIGHT;

EID: 68949207222     PISSN: 13555146     EISSN: None     Source Type: Journal    
DOI: 10.1192/apt.bp.108.005561     Document Type: Article

References (51)

1. Allen AJ, Kurlan RM, Gilbert DL, et al (2005) Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders. Neurology; 65: 1941-9.
2. American Academy of Child and Adolescent Psychiatry (2002) Practice parameter for the use of stimulant medications in the treatment of children, adolescents and adults. Journal of the American Academy of Child and Adolescent Psychiatry; 41: s26-49.
3. Barkley RA, DuPaul GJ, McMurray MB (1991) Attention deficit disorder with and without hyperactivity: clinical response to three dose levels of methylphenidate. Pediatrics; 87: 519-31.
4. Berger S, Dhala A, Friedberg D (2004) Sudden cardiac death in infants, children, and adolescents. Pediatric Clinics of North America; 46: 221-34.
5. Biederman J, Swanson JM, Wigal SB, et al (2005) Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, flexible-dose study. Pediatrics; 116: e777-84.
6. Bradley C (1937) The behavior of children receiving benzedrine. American Journal of Psychiatry; 94: 577-85.
7. Brown WA (1998) Images in psychiatry: Charles Bradley MD. Amercian Journal of Psychiatry; 155: 968.
8. Carlson GA, Dunn D, Kelsey D, et al (2007) A pilot study for augmenting atomoxetine with methylphenidate: safety of concomitant therapy in children with attention deficit/hyperactivity disorder. Child and Adolescent Psychiatry and Mental Health; 1: 10.
9. Chamberlain S, del Campo N, Dowson J, et al (2007) Atomoxetine improved response inhibition in adults with attention deficit/hyperactivity disorder. Biological Psychiatry; 62: 977-84.
10. Cleland G (2007) Drugs 'of no benefit' to hyperactive children. Daily Telegraph; 12 November: p. 10.
11. Conners CK, Levin ED, Sparrow E, et al (2001) Multimodal treatment of ADHD in the MTA: an alternative outcome analysis. Journal of the American Academy of Child and Adolescent Psychiatry; 40: 159-67.
12. Duff G (2005) Strattera (Atomoxetine) - Risk of Hepatic Disorders. Medicines and Healthcare products Regulatory Agency (http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/ Safetywarningsandmessagesformedicines/CON1004252).
13. Duff G (2006) Strattera▼ (Atomoxetine) - Conclusions of Risk:benefit Review. Medicines and Healthcare products Regulatory Agency (http://www.mhra.gov.uk/home/groups/comms-po/documents/ websiteresources/con2023220.pdf).
14. Dunn DW, Austin JK, Harezlak J, et al (2003) ADHD and epilepsy in childhood. Developmental Medicine and Child Neurology; 45: 50-4.
15. Eli Lilly (2005) Straterra Prescribing Information. Eli Lilly.
16. Ferraro L, Antonelli T, Tanganelli S, et al (1999) The vigilance promoting drug modafinil increases extracellular glutamate levels in the medial preoptic area and the posterior hypothalamus of the conscious rat: prevention by local GABA receptor blockade. Neuropsychopharmacology; 20: 346-56.
17. Geshi E, Kimura T, Yoshimura M, et al (2005) A single nucleotide polymorphism in the carboxylesterase gene is associated with the responsiveness to imidapril medication and the promoter activity. Hypertension Research; 28: 719-25.
18. Greenhill LL, Halperin JM, Abikoff H (1999) Stimulant medications. Journal of the American Academy of Child and Adolescent Psychiatry; 38: 503-12.
19. Gualtieri CT (2002) Psychostimulants, dopamine agonists and amantadine. In Brain Injury and Mental Retardation: Psychopharmacology and Neuropsychiatry. Lippincott Williams and Wilkins.
20. Hunt R, Minderaa R, Cohen D (1985) Clonidine benefits children with attention deficit hyperactivity disorder and hyperactivity: report of a double-blind placebo-crossover therapeutic trial. Journal of the American Academy of Child Psychiatry; 24: 617-29.
21. Jadad AR, Boyle M, Cunningham C, et al (1998) The Treatment of Attention Deficit/Hyperactivity Disorder: An Evidence Report. Agency for Healthcare Research and Quality, US Department of Health and Human Services.
22. Jensen PS, Arnold LE, Swanson JM, et al (2007) 3-year follow-up of the NIMH MTA study. Journal of the American Academy of Child and Adolescent Psychiatry; 46: 989-1002.
23. Katz R (2006) Action Memo for NDA 20-717/SE-021, for the Use of Provigil (Modafinil) Tablets in the Treatment of Pediatric Patients with Narcolepsy. Food and Drug Administration (http://www.fda.gov/cder/ foi/esum/2007/020717s021_Modafinil_Clinical_BPCA.pdf).
24. Michelson D, Faries D, Wernicke J, et al (2001) Atomoxetine in the treatment of children and adolescents with attention-deficit/ hyperactivity disorder: a randomized, placebo-controlled, dose response study. Pediatrics; 108: e83.
25. Michelson D, Buitelaar JK, Danckaerts M, et al (2004) Relapse prevention in pediatric patients with ADHD treated with atomoxetine: a randomized, double-blind, placebo-controlled study. Journal of the American Academy of Child and Adolescent Psychiatry; 43: 896-904.
26. Molina BSG, Flory K, Hinshaw SP, et al (2007) Delinquent behavior and emerging substance in the MTA at 36 months: prevalence, course and treatment effects. Journal of the American Academy of Child and Adolescent Psychiatry; 46: 1028-40.
27. MTA Cooperative Group (1999a) A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD. Archives of General Psychiatry; 56: 1073-86.
28. MTA Cooperative Group (1999b) Moderators and mediators of treatment response for children with attention-deficit/hyperactivity disorder. The Multimodal Treatment Study of Children with ADHD. Archives of General Psychiatry; 56: 1088-96.
29. National Institute for Clinical Excellence (2000) Guidance on the Use of Methylphenidate (Ritalin, Equasym) for Attention-Deficit/ Hyperactivity Disorder (ADHD) in Childhood. NICE.
30. National Institute for Health and Clinical Excellence (2008) Diagnosis and Management of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children, Young People and Adults. NICE.
31. Newcorn JH, Kratochvil CJ, Allen AJ, et al (2008) Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response. American Journal of Psychiatry; 165: 721-30.
32. Nissen SE (2006) ADHD drugs and cardiovascular risk. New England Journal of Medicine; 354: 1445-8.
33. Prasad S, Harpin V, Poole L, et al (2007) A multi-centre, randomised, open-label study of atomoxetine compared with standard current therapy in UK children and adolescents with attention-deficit/hyperactivity disorder (ADHD). Current Medical Research and Opinion; 23: 379-94.
34. Prasad S, Steer C (2008) Switching from neurostimulant therapy to atomoxetine in children and adolescents with attention-deficit hyperactivity disorder: clinical approaches and review of current available evidence. Pediatric Drugs; 10: 39-47.
35. Rappley MD, Moore JW, Dokken D (2006) ADHD drugs and cardiovascular risk. New England Journal of Medicine; 354: 2296.
36. Rapport MD, Stoner G, DuPaul G, et al (1985) Methylphenidate in hyperactive children: differential effects of dose on academic learning, and social behavior. Journal of Abnormal Child Psychology; 13: 227-43.
37. Rapport MD, Denney C (1997) Titrating methylphenidate in children with attention-defict/hyperactivity disorder: is body mass predictive of clinical response? Journal of the American Academy of Child and Adolescent Psychiatry; 36: 523-30.
38. Scottish Intercollegiate Guidelines Network (2005) Diagnosis and Management of Epilepsies in Children and Young People. SIGN.
39. Singer H, Brown J, Quaskey S, et al (1995) The treatment of attention deficit hyperactivity disorder in Tourette's syndrome: a double blind placebo-controlled study with clonidine and desimipramine. Pediatrics; 95: 74-81.
40. Spencer T, Biederman J, Wilens T, et al (1993) Nortriptyline treatment of children with attention-deficit hyperactivity disorder and tic disorder or Tourette's syndrome. Journal of the American Academy of Child and Adolescent Psychiatry; 32: 205-10.
41. Spencer T, Biederman J, Heiligenstein J, et al (2001) An open-label dose ranging study of atomoxetine in children with attention deficit hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology; 11: 251-65.
42. Spencer TJ, Sallee FR, Gilbert DL, et al (2008) Atomoxetine treatment of ADHD in children with comorbid Tourette syndrome. Journal of Attention Disorders; 11: 470-81.
43. Swanson JM, Elliot GR, Greenhill LL, et al (2007a) Effects of stimulant medication on growth rates across 3 years in the MTA follow up. Journal of the American Academy of Child and Adolescent Psychiatry; 46: 1015-27.
44. Swanson JM, Hinshaw SP, Arnold LE, et al (2007b) Secondary evaluations of the MTA 36-month outcomes: propensity score and growth mixture model analyses. Journal of the American Academy of Child and Adolescent Psychiatry; 46: 1003-14.
45. Tan M, Appleton R (2005) Attention deficit and hyperactivity disorder, methylphenidate, and epilepsy. Archives of Disease in Childhood; 90: 57-9.
46. Tourette's Syndrome Study Group (2002) Treatment of ADHD in children with tics: a randomized controlled trial. Neurology; 58: 527-36.
47. Vetter VL, Elia J, Erickson C, et al (2008) Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit/hyperactivity disorder: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing. Circulation; 117: 2407-23.
48. Wernicke JF, Holdridge KC, Lin J, et al (2007) Seizure risk in patients with attention-deficit-hyperactivity disorder treated with atomoxetine. Developmental Medicine and Child Neurology; 49: 498-502.
49. Wilens TE (2004) Attention deficit/hyperactivity disorder and substance use disorders: the nature of the relationship, subtypes at risk and treatment issues. Psychiatric Clinics of North America; 27: 283-301.
50. Wilens T, McBurnett K, Stein M, et al (2005) ADHD treatment with once-daily OROS methylphenidate: final results from a long-term open-label study. Journal of the American Academy of Child and Adolescent Psychiatry; 44: 1015-23.
51. Winterstein AG, Gerhard G, Shuster J, et al (2007) Cardiac safety of central nervous system stimulants in children with attention deficit/ hyperactivity disorder. Pediatrics; 120: e1494-501.